[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"food-allergies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:food-allergies":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,72,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100620558","a-long-term-observational-follow-up-study-of-children-and-young-people-who-underwent-an-18-month-course-of-oral-immunotherapy-treatment-for-peanut-egg-or-milk-allergy-5-15-years-post-treatment-100620558",false,"NCT07359183","A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)","Long Term Outcomes Associated With Attainment of Remission Following Oral Immunotherapy to Peanut, Egg and Cow's Milk (LPEM Study)","LPEM","Inclusion Criteria:\n\n* Previous participant of PEAT, PrEMO, PPOIT-001 or PPOIT-002 parent study\n* Received at least one dose of OIT treatment in the parent study\n* Written informed consent from participant and\u002For parent\u002Fguardian (if below 18 years of age)\n\nExclusion Criteria:\n\n-Have any conditions that, in the opinion of the investigator, precludes participation for reason of safety","ALL",{"count":19,"type":20},147,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy. It aims to:\n\n• Compare long-term changes in health-related quality of life (HRQL) at 5-15 years after stopping OIT in participants who achieved remission and those who did not.\n\nParticipants will attend a single follow-up visit for:\n\n* A blood test\n* Skin prick test (SPT)\n* Allergy questionnaires",[24,25,26,27],"Food Allergies","Peanut Allergies","Egg Allergy","Milk Allergy","RECRUITING","2026-01-29",{"date":31,"type":32},"2026-02-02","ACTUAL",{"date":34,"type":32},"2026-01-13",{"date":36,"type":20},"2027-01",{"name":38,"class":39},"Murdoch Childrens Research Institute","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100598585","omalizumab-for-plant-food-allergy-due-to-sensitization-to-ltp-or-profilin-100598585","NCT07073404","Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin","Omalizumab for the Monotherapy Treatment of Patients With Allergy to Foods of Plant Origin Due to Sensitization to Lipid Transfer Proteins (LTPs) and Profilin","Omlyclo","Inclusion Criteria:\n\n* Males or females aged 14-55 years who sign the informed consent (IC) for the study and Biobank sample storage.\n* Allergy to plant foods due to sensitisation to LTP, patients allergic to profilin confirmed by a suggestive clinical history, positive skin tests and specific IgE to Pru p 3 (peach LTP) and Pho d 2 (Phoenix dactylifera profilin).\n* Positive oral challenge test (OPT) to peach and at least one other food in patients allergic to LTP and positive oral challenge test to melon and at least one other food in patients allergic to profilin.\n* Selection of a group of LTP-allergic individuals with therapeutic failure after treatment with ITSL-Pru p 3.\n\nExclusion Criteria:\n\n* Pregnancy and lactation.\n* Immunological diseases; treatment with immunomodulatory and\u002For blocking drugs.\n* Mental illness, which makes it impossible to follow and adhere to treatment (e.g. major depression, psychosis, etc.).\n* Severe atopic dermatitis according to SCORAD 5: FEV1\\\u003C70% (this test will be carried out as a priority in patients with a previous diagnosis of asthma).\n* Inflammation in the oral cavity with severe symptoms, as well as with oral surgery in the previous 7 days.\n* Immunotherapy with pollens in the previous 2 years.\n* Subjects unable to comply with the schedule of visits during the study, as well as due to the consumption of the food under investigation, for example, due to work difficulties.","14 Years","55 Years",{"count":52,"type":20},37,"Omalizumab has demonstrated efficacy, increasing the tolerance threshold in patients with multiple food allergies, as well as reducing the risk of severe reactions when used as monotherapy. This favors improving the reactivity profile of patients with food allergy. In our setting, plant allergy caused by sensitization to panallergens such as lipid transfer proteins (LTPs) and profilins entails important limitations for the consumption of a healthy diet due to the extensive dietary restrictions.\n\nThe main objective of this project is to analyze the efficacy of treatment with omalizumab administered every 2-4\u002Fweeks, used in monotherapy in patients with plant allergy due to sensitization to profilin and LTPs and those patients in whom sublingual immunotherapy with Pru p 3 (peach LTP), has not been effective, by performing a before-after study we will evaluate the changes in clinical reactivity to LTP (peach) and profilin (melon) and the changes immunological effect after omalizumab intervention. In addition, we will evaluate the changes in reactivity to at least one food other than peach and melon in the different sensitization profiles.",[24],[56,57,58,59,60,61],"Omalizumab","FOOD ALLERGIES","LTP","Profilins","Allergy desensitization","Lipid transfer proteins","NOT_YET_RECRUITING","2025-08-06",{"date":65,"type":32},"2025-08-12",{"date":67,"type":20},"2026-01",{"date":69,"type":20},"2027-12",{"name":71,"class":39},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":40},"100592745","endophenotyping-for-plant-based-food-allergy-diagnosis-tolerance-biomarkers-and-mechanisms-in-microneedle-immunotherapy-100592745","NCT06997432","Endophenotyping for Plant-based Food Allergy Diagnosis, Tolerance Biomarkers, and Mechanisms in Microneedle Immunotherapy","Study of the Clinical and Immunological Implications of Maintaining in the Diet the Maximum Tolerated Dose Identified in a Controlled Food Exposure Test According to the Sensitization Profile to LTPs","Inclusion Criteria:\n\n* Women and men\n* 14-65 years-old\n* Peach allergy due to sensitization to LTP confirmed by skin tests and\u002For IgEe positive to Pru p 3.\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Pregnant of lactating women.\n* Patients with immunological diseases, mental illness or severe atopic dermatitis.\n* Patients treated with immunomodulators and\u002For β-blockers\n* Patients with forced expiratory volume (FEV1)\\\u003C70%.","65 Years",{"count":81,"type":20},32,"In relation to the prognosis of vegetable FA (VFA), in contrast to other food allergies (FA), which disappear naturally with time, VFA tends to persist into adulthood and to the appearance of new sensitizations to other vegetables. The paradigm of early intervention in patients with risk factors for developing FA has changed in recent years, with evidence that maintaining a controlled diet with foods with potential allergic risk in a population of children at risk has shown efficacy in early intervention. An important aspect would be the selection of the dose of the food to be included in the diet. In this sense, recent studies on the standardization of the double-blind placebo-controlled oral challenge test (DBPCFC) in allergic patients to Lipid Transfer Proteins (LTP) with known amounts of Pru p 3 (peach LTP), have observed that the maximum tolerated dose (MTD) was equivalent to 40 grams of peach with skin. Based on these results and those obtained in the pediatric population, this study aims to evaluate whether the maintenance in the diet of a DMT evaluated in a DBPCFC could influence tolerance (desensitization) to the food at both clinical and immunological levels.",[24],[85,60,86],"Vegetable food allergy","Lipid Transfer Proteins","2025-05-21",{"date":89,"type":32},"2025-05-30",{"date":91,"type":20},"2025-06",{"date":69,"type":20},{"name":71,"class":39},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100586549","food-challenge-at-home-or-in-medical-practice---the-foodchomp-study-100586549","NCT06916819","Food Challenge at Home or in Medical Practice - the FoodCHOMP Study","Food Challenge at Home or in Medical Practice - a Multi-center Randomized Control Trial - FoodCHOMP Study","CHOMP","Inclusion Criteria:\n\n1. Negative (\\\u003C3mm) fresh or extract skin testing to the food implicated within their allergy label\n2. Aged greater than 18 years\n\nExclusion Criteria:\n\n* Evidence of prior sensitisation to challenge food 0 Defined as previously positive skin testing or allergen specific IgEs if available\n* Pregnancy\n* Patients with poorly controlled asthma - defined as an ACQ5 scores \\>1 at the time of enrolment\n* Patients with a history of food reactions that is not-consistent with an IgE mediated process; i.e. exclusively gastrointestinal symptoms, FPIES\n* Patients with a clear history of food-dependent exercise induced anaphylaxis\n* Patients on a concurrent medication which may influence the outcome of the challenge;\n* Antihistamine therapy; Patients receiving more than stress dose steroids (i.e. \\> 50mg QID hydrocortisone \\[or steroid equivalent\\]); Omalizumab\n* Any other illness that, in the investigator's judgement, will substantially increase the risk associated with subject's participation in this study","18 Years",{"count":104,"type":20},120,"INTERVENTIONAL",[107],"NA","This is a pilot, multi-centre, randomised clinical trial evaluating the safety and feasibility of a home-based oral food challenge in adults with low-risk food allergy labels. Eligible participants are aged 18 years or older and have a self-reported food allergy with negative skin prick testing to the implicated food. Participants will be randomised to either a home-based or standard in-clinic food challenge. The primary aim is to determine the safety of home challenges, measured by the rate of immune-mediated adverse events. Secondary aims include feasibility of recruitment and delivery, protocol adherence, quality of life, and food reintroduction outcomes.",[24],[111,112,113],"Food allergy","Food allergy label","Food Challenge","2025-04-15",{"date":116,"type":32},"2025-04-17",{"date":118,"type":32},"2025-04-16",{"date":120,"type":20},"2026-12-01",{"name":122,"class":123},"Austin Health","OTHER_GOV",2]